Literature DB >> 27739620

Effectiveness of continuous glucose monitoring in children, adolescents, and young adults with poorly controlled type 1 diabetes.

Kevin R Lewis1, Susan McCrone2, Pamela Deiriggi3, Sachin Bendre4.   

Abstract

OBJECTIVE: The purpose of this study was to determine the effect of continuous glucose monitoring (CGM) on glycemic control in children, adolescents, and young adults ages 7-21 years with poorly controlled diabetes HbA1c 9.0% or more (74 mmol/mol IFCC).
MATERIALS AND METHODS: The primary outcome was improvement in HbA1c. The secondary outcome included self-reported hypoglycemia. This 12-week study used a prospective, one-group, pre- and posttest pre-experimental design with a convenience sample. The study used the Medtronic Guardian CGM with Enlite Sensor. RESULTS AND
CONCLUSIONS: Thirty-three subjects enrolled in the study. The mean age of the participants was 15.57 years, range was 11-20 years, 47.6% were male, and 52.4% were female. Twenty-one (63.6%) completed the final study visit. There was a clinically and statistically significant reduction of 1.46 (SD = 1.6711) (p = .001) in HbA1c at 12 weeks. Fifteen of the 21 participants (71.4%) had an HbA1c reduction of greater than 0.5%. The CGM monitor was worn a mean of 4.262 days a week. None of the subjects reported significant hypoglycemia while wearing the monitor. CGM was effective in improving glycemic control in this population with poorly controlled diabetes.
© 2016, Wiley Periodicals, Inc.

Entities:  

Keywords:  Adolescents; adolescents & uncontrolled; children; continuous glucose monitoring; diabetes

Mesh:

Substances:

Year:  2016        PMID: 27739620      PMCID: PMC5482228          DOI: 10.1111/jspn.12162

Source DB:  PubMed          Journal:  J Spec Pediatr Nurs        ISSN: 1539-0136            Impact factor:   1.260


  12 in total

Review 1.  Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association.

Authors:  Janet Silverstein; Georgeanna Klingensmith; Kenneth Copeland; Leslie Plotnick; Francine Kaufman; Lori Laffel; Larry Deeb; Margaret Grey; Barbara Anderson; Lea Ann Holzmeister; Nathaniel Clark
Journal:  Diabetes Care       Date:  2005-01       Impact factor: 19.112

2.  Changing patterns of self-management in youth with type I diabetes.

Authors:  Lynne S Schilling; Kathleen A Knafl; Margaret Grey
Journal:  J Pediatr Nurs       Date:  2006-12       Impact factor: 2.145

3.  Statement by the American Association of Clinical Endocrinologists Consensus Panel on continuous glucose monitoring.

Authors:  Thomas C Blevins; Bruce W Bode; Satish K Garg; George Grunberger; Irl B Hirsch; Lois Jovanovič; Elizabeth Nardacci; Eric A Orzeck; Victor L Roberts; William V Tamborlane; Caitlin Rothermel
Journal:  Endocr Pract       Date:  2010 Sep-Oct       Impact factor: 3.443

4.  Routine sensor-augmented pump therapy in type 1 diabetes: the INTERPRET study.

Authors:  Kirsten Nørgaard; Andrea Scaramuzza; Natasa Bratina; Nebojsa M Lalić; Przemyslaw Jarosz-Chobot; Győző Kocsis; Edita Jasinskiene; Christophe De Block; Odile Carrette; Javier Castañeda; Ohad Cohen
Journal:  Diabetes Technol Ther       Date:  2013-02-25       Impact factor: 6.118

Review 5.  Personal continuous glucose monitoring (CGM) in diabetes management: review of the literature and implementation for practical use.

Authors:  M Joubert; Y Reznik
Journal:  Diabetes Res Clin Pract       Date:  2011-12-28       Impact factor: 5.602

6.  Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes.

Authors:  Richard M Bergenstal; William V Tamborlane; Andrew Ahmann; John B Buse; George Dailey; Stephen N Davis; Carol Joyce; Tim Peoples; Bruce A Perkins; John B Welsh; Steven M Willi; Michael A Wood
Journal:  N Engl J Med       Date:  2010-06-29       Impact factor: 91.245

7.  Continuous glucose monitoring and intensive treatment of type 1 diabetes.

Authors:  William V Tamborlane; Roy W Beck; Bruce W Bode; Bruce Buckingham; H Peter Chase; Robert Clemons; Rosanna Fiallo-Scharer; Larry A Fox; Lisa K Gilliam; Irl B Hirsch; Elbert S Huang; Craig Kollman; Aaron J Kowalski; Lori Laffel; Jean M Lawrence; Joyce Lee; Nelly Mauras; Michael O'Grady; Katrina J Ruedy; Michael Tansey; Eva Tsalikian; Stuart Weinzimer; Darrell M Wilson; Howard Wolpert; Tim Wysocki; Dongyuan Xing
Journal:  N Engl J Med       Date:  2008-09-08       Impact factor: 91.245

8.  Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes.

Authors:  Tadej Battelino; Moshe Phillip; Natasa Bratina; Revital Nimri; Per Oskarsson; Jan Bolinder
Journal:  Diabetes Care       Date:  2011-02-19       Impact factor: 19.112

9.  Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study.

Authors:  Denis Raccah; Véronique Sulmont; Yves Reznik; Bruno Guerci; Eric Renard; Hélène Hanaire; Nathalie Jeandidier; Marc Nicolino
Journal:  Diabetes Care       Date:  2009-09-18       Impact factor: 19.112

10.  Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes.

Authors:  Roy W Beck; Bruce Buckingham; Kellee Miller; Howard Wolpert; Dongyuan Xing; Jennifer M Block; H Peter Chase; Irl Hirsch; Craig Kollman; Lori Laffel; Jean M Lawrence; Kerry Milaszewski; Katrina J Ruedy; William V Tamborlane
Journal:  Diabetes Care       Date:  2009-08-12       Impact factor: 19.112

View more
  3 in total

1.  Factory-Calibrated Continuous Glucose Sensors: The Science Behind the Technology.

Authors:  Udo Hoss; Erwin Satrya Budiman
Journal:  Diabetes Technol Ther       Date:  2017-05       Impact factor: 6.118

2.  Technological Ecological Momentary Assessment Tools to Study Type 1 Diabetes in Youth: Viewpoint of Methodologies.

Authors:  Mary Katherine Ray; Alana McMichael; Maria Rivera-Santana; Jacob Noel; Tamara Hershey
Journal:  JMIR Diabetes       Date:  2021-06-03

Review 3.  Use of continuous glucose monitoring trend arrows in the younger population with type 1 diabetes.

Authors:  Nancy Elbarbary; Othmar Moser; Saif Al Yaarubi; Hussain Alsaffar; Adnan Al Shaikh; Ramzi A Ajjan; Asma Deeb
Journal:  Diab Vasc Dis Res       Date:  2021 Nov-Dec       Impact factor: 3.291

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.